Immunovant, Inc. IMVT
35.71 USD +0.56 (+1.59%)
At closeNov 10, 2026, 4:09 PM EST
35.17 -0.54 -1.51%
After hours · Nov 10, 4:09 PM ET
34.83 Day range 35.96
21.86 52-week range 45.42
- YTD
- +40.48%
- 1 year
- +52.80%
- Market cap
- 7.39B
- EPS (ttm)
- -2.56
- Shares out
- 206.95M
- Forward P/E
- -12.98
- YTD return
- +40.48%
- 1-year return
- +52.80%
- Volume
- 1.64M
- Avg volume
- 1.44M
- Open
- 35.15
- Previous close
- 35.15
- Day's range
- 34.83 – 35.96
- 52-week range
- 21.86 – 45.42
- Beta
- 0.94
- Analysts
- Buy
- Price target
- 48.38 (+35.5%)
- Earnings date
- Feb 16, 2027
5D +6.30 (+21.35%)
Key statistics
- Enterprise value
- 6.55B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 11.24
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -230.54M
- Total cash
- 722.27M
- Total debt
- 0
- Return on equity
- -86.51%
- Short % of float
- 19.62%
- 50-day average
- 32.98
- 200-day average
- 32.17
Analyst view
Consensus: buy
Buy
Price target (mean) 48.38 +35.5% upside
Now 35.71
- Target (low)
- 30.00
- Target (mean)
- 48.38
- Target (high)
- 62.00
Ratings (0m) 17 13 buy · 4 hold · 0 sell
- Strong buy2
- Buy11
- Hold4
- Sell0
- Strong sell0
Next earnings
Feb 16, 2027
Expected Feb 16, 2027. Consensus EPS estimate -0.67107.
Financials — quick view
IMVT Revenue — quarterly 0
IMVT Net income — quarterly -153.22M
IMVT EPS — quarterly -0.75
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 16, 2027 | Dec 30, 2026 | -0.7294 | — | — | — |
| Nov 9, 2026 | Sep 30, 2026 | -0.73701 | -0.47 | +0.27 | +36.23% |
| Aug 6, 2026 | Jun 30, 2026 | -0.6289 | -0.75 | -0.12 | -19.26% |
| May 20, 2026 | Mar 31, 2026 | -0.59202 | -0.73 | -0.14 | -23.31% |
| Feb 6, 2026 | Dec 31, 2025 | -0.72 | -0.61 | +0.11 | +15.28% |
| Nov 10, 2025 | Sep 30, 2025 | -0.72 | -0.73 | -0.01 | -1.39% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 10, 2026 | Truist Securities | main | Hold | Hold |
| Nov 10, 2026 | Wells Fargo | main | Overweight | Overweight |
| Aug 4, 2026 | JP Morgan | main | Overweight | Overweight |
| Jun 30, 2026 | Citigroup | main | Buy | Buy |
| May 26, 2026 | Guggenheim | main | Buy | Buy |
| May 22, 2026 | Truist Securities | main | Hold | Hold |
About Immunovant, Inc.
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- immunovant.com
News
Truist Securities Maintains Hold on Immunovant, Raises Price Target to $33 
Wells Fargo Maintains Overweight on Immunovant, Raises Price Target to $47 
Immunovant Meets Primary Endpoint In Difficult-To-Treat Rheumatoid Arthritis Study 
KKR, Constellation Energy On Deck Monday As Private Credit, Power Face Test 
Immunovant Q1 2027 Earnings Call: Complete Transcript 
Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session 
Why Applied Digital Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket 
Immunovant Ends Autoimmune Skin Disorder Program 
Roivant And Immunovant Say Topline Results From Period 1 Of Proof-of-concept Trial of IMVT-1402 (Imeroprubart) For Cutaneous Lupus Erythematosus Did Not Achieve Statistical Significance On The Primary Endpoint 
Immunovant Q1 2027 Earnings Call: Complete Transcript
Your note
Sign in to keep a note on IMVT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARNETT EVA RENEE | Chief Financial Officer | Sale | Apr 15, 2025 | 396,774 |
| GEFFNER MICHAEL | Officer | Sale | Oct 21, 2025 | 217,958 |
| GIRÃO TIAGO M | Chief Financial Officer | Sale | Jul 22, 2026 | 240,798 |
| GLORIA MELANIE | Chief Operating Officer | Sale | Aug 19, 2026 | 219,301 |
| LEVINE MARK S | Officer | Sale | Nov 19, 2024 | 319,228 |
| MACIAS WILLIAM L | Officer | Sale | Feb 18, 2025 | 357,353 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 7.84% | 16,186,469 | 578.02M | Jun 29, 2026 |
| Deep Track Capital, Lp | 4.52% | 9,341,151 | 333.57M | Jun 29, 2026 |
| Blackrock Inc. | 3.48% | 7,180,897 | 256.43M | Jun 29, 2026 |
| Farallon Capital Management LLC | 2.81% | 5,805,000 | 207.30M | Jun 29, 2026 |
| Baker Bros. Advisors, LP | 2.63% | 5,435,220 | 194.09M | Jun 29, 2026 |
| State Street Corporation | 2.24% | 4,617,005 | 164.87M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 2.47% | 5,092,337 | 181.85M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.26% | 2,600,086 | 92.85M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.09% | 2,251,148 | 80.39M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.02% | 2,107,163 | 75.25M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 0.91% | 1,881,798 | 67.20M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 0.68% | 1,408,872 | 50.31M | Sep 29, 2026 |